Cellectis (CLLS) Capital Expenditures (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -114.09% |
| Dec 31, 2025 | 259.27% |
| Sep 30, 2025 | -287.21% |
| Jun 30, 2025 | 22.78% |
| Mar 31, 2025 | -108.56% |
| Dec 31, 2024 | 694.08% |
| Sep 30, 2024 | 25.14% |
| Jun 30, 2024 | -376.15% |
| Mar 31, 2024 | -127.35% |
| Dec 31, 2023 | 353.82% |
| Sep 30, 2023 | -16.30% |
| Jun 30, 2023 | -26.76% |
| Mar 31, 2023 | -104.82% |
| Dec 31, 2022 | 1,086.61% |
| Sep 30, 2022 | 51.04% |
| Jun 30, 2022 | -46.17% |
| Mar 31, 2022 | -101.70% |
| Dec 31, 2021 | 897.68% |
| Sep 30, 2021 | 15.36% |
| Jun 30, 2021 | 33.46% |
| Mar 31, 2021 | -111.33% |
| Dec 31, 2020 | 1,241.31% |
| Sep 30, 2020 | 54.68% |
| Jun 30, 2020 | -76.68% |
| Mar 31, 2020 | -134.12% |
| Dec 31, 2019 | 524.26% |
| Sep 30, 2019 | -82.26% |
| Jun 30, 2019 | -65.51% |
| Mar 31, 2019 | -125.40% |
| Dec 31, 2018 | 678.59% |
| Sep 30, 2018 | -123.77% |
| Jun 30, 2018 | 13.23% |
| Mar 31, 2018 | -114.94% |
| Dec 31, 2017 | 825.26% |
| Sep 30, 2017 | 41.69% |
| Jun 30, 2017 | -84.06% |
| Mar 31, 2017 | -102.08% |
| Dec 31, 2016 | 1,158.80% |
| Sep 30, 2016 | 8.88% |
| Jun 30, 2016 | 62.77% |
| Mar 31, 2016 | -1,061.97% |
| Dec 31, 2015 | -221.40% |
| Sep 30, 2015 | 55.16% |
| Jun 30, 2015 | 85.92% |